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Cancer in humans and animals is a multistage disease which
results from multiple mutational events (Guyton and Kensler,
1993). Reactive oxygen species (ROS) (Wagner et al, 1992), lipid
hydroperoxides (Ames et al, 1993) and malondialdehyde (MDA)
(Mukai and Goldstein, 1975; Basu and Mannett, 1983) are muta-
genic. Therefore they are mediators of phenotypic and genotypic
alterations, due to multiple single mutations, which will eventually
result in neoplasia events (Guyton and Kensler, 1993). Genes that
are critically involved in cell growth are particularly vulnerable.
Examples are the proto-oncogenes (Crawford et al, 1988) and the
tumour suppressor genes (Ribeiro et al, 1996).
Lipid peroxidation (LPO) in cancer, because of uncontrolled
free radical involvement, leads to several changes in cancer cells
(Eriksson and Andersson, 1992). Glutathione (GSH) and GSH
peroxidase (GS-Px) salvage the cell from LPO damage, particu-
larly from damage to the membranes (Masotti et al, 1988). The
salvaging process occurs when peroxy-polyunsaturated fatty acids
(peroxy-PUFAs) are converted to hydroxy-FAs by GS-Px at the
expense of GSH (Sevanian et al, 1983), rather than allowing LPO
to go to completion with the production of short-chain FAs and
MDA.
GSH and GS-Px also prevent other oxyradical damage,
especially that inflicted on proteins and DNA. They acted as
members of the antioxidant system of the cell by degrading
hydrogen peroxide before it is converted to a hydroxyl radical
(OH) (Halliwell and Gutteridge, 1992). Hydroxyl radicals can
cause mutagenic damages to DNA by hydroxylation of the bases
of DNA, especially guanine (G), to form 8-hydroxy-G (Floyd,
1990). This mutagenic event causes a change in base pairing from
a G:C base pair to a 8-OH-G:A pair, which will eventually lead to
a substitution of G by T in the subsequent progeny strand, causing
a G to T transversion (Kasai and Nishimura, 1991).
The GSH/GSH-s-transferase (GST) system detoxifies muta-
gens, including those derived from ROS. In tumours, the GST
P1-isoenzyme is strongly and persistently expressed (Campbell
et al, 1991) but it was reported that the A- and M-isoenzymes
appeared to be down-regulated or simply not expressed in many
tumours (Gajewska and Szczypka, 1992). Miura et al (1997)
suggested that the expression of GST-P1 may be linked directly to
malignant transformations and may be regulated by oncogenes
such as c-jun and c-fos (Tsuchida and Sato, 1992). In gastric
cancer tissue the expression of GST-P1 was increased at the
expense of GST-A (Peters et al, 1990). However, it was found that
in lung cancer, renal cancer and hepatomas the expression of
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Summary Oxyradicals are involved in multiple mutational events and can contribute to the conversion of healthy cells to cancer cells.
Glutathione (GSH) and the GSH-replenishing enzymes keep the antioxidant status of normal cells at a level where they can avert oxyradical
derived mutations. The aim of this study was to determine whether in cancer cells the GSH-replenishing, GSH antioxidant and GSH-depleting
enzymes were not at appropriate levels and therefore not able to protect cancer cells adequately against oxyradical-induced mutations.
Cancer of the oesophagus was chosen since it is the most common gastrointestinal malignancy in South African Blacks. Biopsies and blood
from 31 patients with cancer of the oesophagus and 29 non-cancer patients were assessed for these enzymes. The mean activity of the
antioxidant and depleting enzyme GSH-peroxidase was elevated significantly by twofold in the cancer tissue compared to normal tissue.
However, the activity of the replenishing enzyme GSSG-reductase and the level of the depleting enzyme GSH-s-transferase P1-isoenzyme
were significantly reduced by 23% and 33% respectively. As in a previous paper we found that GSH was depleted and g-glutamine
transpeptidase was diminished in oesophageal cancer. There can be two reasons for GSH depletion. Firstly, elevated GSH–peroxidase will
use more GSH in an attempt to cope with the excessive production of oxyradicals as revealed by elevated lipid peroxidation; this was, as
shown by us before, elevated sixfold in oesophageal cancer. Secondly, if little replenishment of GSH occurred the level of GSH would become
lower. This was confirmed by our findings that the activities of the replenishing enzymes were significantly diminished in oesophageal cancer
tissue. Contrary to what was expected, the other depleting enzyme GSH-s-transferase P1 was not elevated in cancer tissue but was
significantly lower. However, in the blood of the same patients it was significantly elevated. An explanation for this phenomenon is that,
although the production of GST-P1 was enhanced in cancer, it did not show because it was rapidly extruded into the blood by an unknown
mechanism operational only in cancer cells.
Keywords: GSH-peroxidase; GSSG-reductase; GSH-s-transferase P1-isoenzyme; oesophageal cancer
32
British Journal of Cancer (1999) 80(1/2), 32–37
© 1999 Cancer Research Campaign
Article no. bjoc.1998.0317
Received 14 October 1997
Revised 21 October 1998
Accepted 5 November 1998
Correspondence to: MMJ OosthuizenGS-Px, GS-R and GST-P1 in oesophageal cancer 33
British Journal of Cancer (1999) 80(1/2), 32–37 © Cancer Research Campaign 1999
GST-P1 was both increased and reduced (Gajewska and Szczypka,
1992). What is the case then in oesophageal cancer? In 80% of the
patients, the resected primary oesophageal cancer showed that the
RNA transcript levels of GST-P1 were significantly elevated
(Ishioka et al, 1991). However, in contrast, Sasano et al (1993)
found that with both in situ hybridization and immunohisto
chemistry assessments, GST-P1 was detected as strongly in
normal oesophageal mucosa as in cancer. Only 35% of cases
showed an increase of GST-P1 in cancer compared to normal
tissue. Peterset al (1993) also found that GST-P1 levels were low
in a high number of patients with oesophageal cancer. Why then
the apparent high level of GST-P1 expression but low amounts
present in cancer tissue? The answer might be found in the obser-
vation that patients with oesophageal cancer have significantly
higher levels of GST-P1 in serum or plasma, which revert back to
a normal level after surgical removal of the tumour (Niitsu et al,
1989; Tsuchida et al, 1989; Fan et al, 1995). This elevated extra-
cellular or plasma GST-P1 enzyme is not the active 46 kDa dimer
enzyme but the inactive monomer of 23 kDa. This monomer is not
released in plasma as a result of the disruption of cells but due to
an energy-dependent efflux process in the cancer cells. In normal
subjects the GST-P1 monomer originates from aggregating
platelets and is responsible for a low background level of GST-P1
in plasma.
We previously found that cancerous tissue of the oesophagus
became depleted of GSH (Hunter et al, 1992). The extracellular
GSH replenishing enzyme gamma-glutamyl transpeptidase (g-GT)
was also significantly depleted (Hunter et al, 1992). The aim of the
present study was to extend the investigation on the intracellular
depletion and replenishment of GSH in oesophageal cancer.
Therefore we assessed the activity of one other replenishing
enzyme GSSG-reductase. The specific activity and levels of
the GSH-depleting enzymes GS-Px, A-, M- and P-isoenzymes
of GSH-s-transferase (Hayes and Pulford, 1995) were also
determined respectively.
MATERIALS AND METHODS
Clinical material
Biopsy specimens were obtained from Black patients who under-
went endoscopy for dysphagia at the gastroenterology clinic at
Baragwanath Hospital, Soweto, South Africa. Patients with
alleged cancer of the oesophagus (cancer group) and volunteers
Table 1 Characteristics of groups studied
Patients Cancer group Control group
Numbers 31 29
Average age (mean ± SEM) 54 ± 5 52 ± 8
Male/female ratio 21/10 18/11
75
60
45
30
15
0
P < 0.0001
Control Cancer
Figure 1 GSSG-reductase activity in oesophageal tissue from normal and cancer patients. (º) mean ± SEM34 RD Levy et al
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having other gastroenterological symptoms but with normal
oesophagogastro-duodenoscopy (control group) were subjected to
biopsies. Normal tissue was not taken from the same cancer patient
to serve as its own control. The reason for that was that the tumour
could migrate upwards while that part of the oesophagus might
still look normal macroscopically. Biopsies further down the
oesophagus, beyond the cancer plaque were very difficult to obtain
as most of the patients were obstructed. The total number of
patients in the cancer group was 31 and in the control group was
29. The sex and mean age for the two groups were similar (see
Table 1). Biopsy specimens were taken for histological and
biochemical evaluation. The latter was performed only after it was
confirmed that the cancer was squamous carcinoma. All patients
with squamous carcinoma had advanced disease (stages 4 and 5;
using the Japanese system). Human Ethics Committee approval
was obtained from the University and Hospital, and informed
consent obtained from all patients.
Biochemical analysis
Immediately after tissue biopsies and blood were taken, the plasma
and specimens for biochemical assessments were snap-frozen in
liquid nitrogen and stored at –70°C until analysed. Tissue speci-
mens were pulverized in a pre-cooled Besman tissue pulverizer at
–80°C and extracted with cold buffered saline on a roller-mixer at
4°C for 30 min. After centrifugation at 9000 g for 15 min at 4°C
the supernatant was analysed within 1 h for the GSH-linked
enzymes at 37°C and its protein content.
The activity of GS-Px was determined by the method of Flohé
and Gunzler (1984). With this method GSSG formation was
continuously monitored in the presence of hydrogen peroxide,
GSH, NADPH and added GS-R. The reduction of GSSG and
subsequent oxidation of NADPH was monitored at A340nm.
The activity of GS-R was determined by the method of Beutler
(1969), which was essentially the same as for GS-Px except that
GSSG was added and GS-R was omitted. FAD was also added to
this assay to ensure that maximum GS-R activity was generated.
The levels of A-, M- and P-isoenzymes of GST were determined
with a quantitative enzyme immunoassay (EIA) obtained from
Biotrin International, Ireland which was used before by others
(Brockmöller et al, 1993; Rees et al, 1995; Vaubourdolle et al,
1996; Vistisen et al, 1997). GSH and g-GT were determined simi-
larly as before by Hunter et al (1992) (results not included).
Protein was determined by the Lowry et al method (1951).
Statistical analysis
The mean of triplicate values for each specimen was subjected to
the non-parametric test of Mann–Whitney to compare cancer and
control groups. A P-value < 0.05 was accepted as statistically
significant.
P = 0.0021
Control Cancer
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Figure 2 GSH-peroxidase activity in oesophageal tissue from normal and cancer patients. (º) mean ± SEMGS-Px, GS-R and GST-P1 in oesophageal cancer 35
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RESULTS AND DISCUSSION
The activity of one of the GSH-replenishing enzymes –
glutathione-reductase – was, contrary to what was found by El-
Sharabasy et al (1993) in breast cancer, significantly reduced in
oesophageal cancer (Figure 1). In addition to this, the intracellular
replenishment of GSH was hampered further because we found
this time, as well as previously, that g-GT, the enzyme responsible
for GSH influx from extracellular sources, was again diminished
in oesophageal cancer (Hunter et al, 1992).
GSH-peroxidase, one of the GSH-depleting enzymes, is a more
efficient metabolizer of hydrogen peroxide than catalase (CAT)
(Simmons and Jamall, 1988). GS-Px is more important than either
superoxide dismutase (SOD) or CAT in preventing peroxidation.
We have found that the activity of GS-Px was significantly
increased in oesophageal cancer tissue compared to normal tissue
(Figure 2). This was in contrast to what was found in colon,
cervical, thyroid and laryngeal cancer where the cancer group had
a lower GS-Px activity than the control group (Jendryczko et al,
1993; Mulder et al, 1995; Bhuvarahamurthy et al, 1996; Durak
et al, 1996). The latter finding was supported by other researchers
who found that the remote humoral effect of extra-hepatic cancers
was that the activities of the liver pro-oxidant enzymes were
increased and the activities of the antioxidant enzymes were
decreased. For example, they found in tumour-bearing rats
injected with hTNF-a that the SOD and GS-Px activities
decreased while the activity of xanthine oxidase increased
(Theologides et al, 1994). Selenium deficiency, as was found in
Chinese cancer patients by other researchers (Chen et al, 1992;
Wasowicz et al, 1994), did not play a roll in cancer of Africans
since we found the activity of SeGS-Px was higher in oesophageal
cancer tissues than in normal tissue. Therefore, we believe that the
enhanced activity of GS-Px in oesophageal cancer tissue of Black
patients was rather due to an attempt of the cancer to cope with the
excessive production of oxyradicals. This excessiveness was
substantiated by a six times greater lipid peroxidation in
oesophageal cancer compared to normal tissue (Levy et al, 1998).
To avert oxyradical damage to membrane lipids, all cells including
cancer cells had to maintain a high GS-Px activity and GSH
content to prevent irreversible lipid peroxidation of PUFAs which
formed short-chain FAs and MDA eventually. However, we found,
as before, that GSH is not properly replenished in oesophageal
cancer (Hunter et al, 1992) and since both GS-Px and GST are
dependent on GSH to perform their antioxidant and detoxification
function they become non-functional as soon as GSH becomes
depleted; thus rendering the cancer cells unprotected against
oxyradicals.
The GSH-s-transferase A-, M- and P-isoenzymes were the other
GSH-depleting enzymes that we investigated. Campbell et al
(1991) found that the isoenzyme GST-P1 was expressed regularly
compared to GST-A which was found only in some neoplasms and
GST-M which was seldom present. This was confirmed by our
results where we found that the levels of GST-P1 were high
enough to be detected while those of the GST-A and M-iso-
enzymes were not, despite the low detection limit of 250 ng l–1 for
the two EIAs. However, we have found that the level of GST-P1 in
cancerous tissue was significantly lower than the level in normal
oesophageal tissue (Figure 3). This was contrary to what others
have found (Tsuchida et al, 1989; Ishioka et al, 1991) although
they determined blood and not tissue levels. However, our results
were not unexpected since a phenomenon was observed in cancer,
where GST-P1 was extruded into the blood as the inactive
monomer (Kura et al, 1996). That would have left the cancer tissue
depleted of the dimer despite a high expression of GST-P1 mRNA.
This might be the reason a consistent high level of immuno-
detectable GST-P1 was found in plasma and serum of patients with
oesophageal and other cancers (Niitsu et al, 1989; Tsuchida et al,
1989; Howie et al, 1990; Fan et al, 1995) (Table 2). Our results, as
obtained from plasma of oesophageal and control patients, support
the concept that GST-P1 was enhanced in cancer but did not show
because it was rapidly extruded into the blood by an unknown
mechanism operational only in cancer cells (Table 3; compare also
2(a)(i) with 2(b)(i) in Table 2.)
In summary, the depletion of the tissue antioxidant GSH
supports the notion that oxyradicals in cancer are not under proper
metabolic protection. GS-Px dispose of the excess pro-oxidant
hydrogen peroxide, but as soon as GSH becomes depleted the
Table 2 Percentage elevated GSH-s-transferase P-isoenzyme content or expression in tissue and blood of patients with oesophageal and other cancers
Number High GST-P High GST-P
Cancer Sample of mRNA protein content Fold References
type patients (% of patients) (% of patients) elevation
(a) Oesophageal
tissue (i) 31 – 27 1.3´ *
(ii) 43 – – 6.0´ Tsuchida et al, 1989
(iii) 25 80 – – Ishioka et al, 1993
(iv) – – 35 – Sasano et al, 1993
Oesophageal (i) 31 – 77 2.2´ *
blood (ii) 15 – 53 – Niitsu et al, 1989
(iii) 43 – 60 – Tsuchida et al, 1989
(iv) 135 – 75 – Fan et al, 1995
Bronchus Plasma 29 – 65 – Howie et al, 1990
*This paper.
Table 3 Blood levels of the GSH-s-transferase P1-isoenzyme in
oesophageal cancer and normal patients expressed as mg L–1
Cancer Control
Mean 32.3 17.5
SEM 3.7 1.5
P-value (Mann–Whitney) 0.0016* –
*P < 0.01 difference highly significant.36 RD Levy et al
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activities or levels of both GS-Px and GST-P are of no conse-
quence. Therefore more mutagenic events will occur since muta-
gens and oxyradicals cannot be detoxified or scavenged by the
impaired enzymes essential for an adequate antioxidant defense
system.
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